Innovent Biologics’ obesity drug has shown success in another pivotal trial, meeting the primary and all key secondary endpoints. In the Phase III GLORY-2 trial (NCT06164873), Xinermei (mazdutide) 9mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results